Compare FMST & CNSY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FMST | CNSY |
|---|---|---|
| Founded | 2005 | N/A |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Other Metals and Minerals | Medical/Dental Instruments |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.3M | 20.6M |
| IPO Year | 2022 | 2016 |
| Metric | FMST | CNSY |
|---|---|---|
| Price | $0.96 | $2.76 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 78.3K | 65.6K |
| Earning Date | 05-21-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 87.61 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $5,213,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.99 | $2.62 |
| 52 Week High | $4.57 | $4.03 |
| Indicator | FMST | CNSY |
|---|---|---|
| Relative Strength Index (RSI) | 31.78 | 32.12 |
| Support Level | N/A | $2.62 |
| Resistance Level | $1.94 | $3.28 |
| Average True Range (ATR) | 0.08 | 0.21 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 5.63 | 37.56 |
Foremost Clean Energy Ltd is an exploration company focused on the identification and development of high potential mineral opportunities in stable jurisdictions. Its Uranium properties includes Eastern Athabasca, and Blue-Sky. Its Lithium properties includes Zoro Lithium Project, JEAN LAKE LITHIUM GOLD PROJECT, Peg North Project, Grass River Claims Project, and JOL LITHIUM PROJECT.
Cerenome Inc is a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted therapeutics, and artificial intelligence to improve outcomes for patients with central nervous system cancers. The Company's CNSide Diagnostics platform supports the detection, molecular characterization, and longitudinal monitoring of CNS cancers through cerebrospinal fluid-based testing. Its therapeutic platform, REYOBIQ (rhenium Re186 obisbemeda), is being evaluated in clinical trials for leptomeningeal metastases, recurrent glioblastoma, and pediatric brain cancers. The data & artificial intelligence platform is designed to integrate diagnostic, molecular, imaging, and clinical data into actionable insights that support precision oncology and therapeutic innovation.